Elite football has always been a realm where marginal gains make the difference between good and great. But every once in a while, a partnership emerges that goes far beyond small optimizations. It redefines what performance, health, and medical innovation can look like.
This is precisely the case in the new collaboration between FC Barcelona and Omniscope.
Together, we use cutting-edge sports medicine with immune diagnostics and longevity science, not only to enhance athlete performance on the field, but also to create health technologies that can benefit fans worldwide.
The heart of our story lies just beyond the cameras. Inside FCB’s Medical Center, Omniscope’s cellular analysis technology is redefining the medical staff´s approach to sports medicine. Instead of relying solely on conventional health metrics, they now have access to the living inner workings of the athletes’’ immune system. This allows Dr Gil Rodas, Head of Medical Research at Barça Innovation Hub, to understand recovery, inflammation, stress responses, and overall physiological readiness. With this depth of insight, decisions about training, rest, and performance can be made with more precision than ever before.
At the center of this collaboration lies Omniscope’s unique approach to decoding the immune system. Rather than treating immune cells as static biomarkers that reveal only snapshots of health, Omniscope views them as dynamic, living indicators that record the body’s continuous interaction with the world. By reading immune cells at extremely high resolution, Omniscope reveals what stresses the body has encountered, how it is adapting, and how its internal defenses and repair systems are functioning. This allows FCB’s medical staff to recognize early signs of imbalance or overtraining long before symptoms arise, enabling interventions that keep athletes healthier and more resilient throughout long seasons.
What makes this collaboration even more remarkable is that its benefits are not limited to professional athletes. Through the Omniscope “osLifetime” platform, fans now have the opportunity to access the same insights as FCB athletes.
osLifetime measures Biomarkers of Aging, with a special emphasis on Immune Aging, which is one of the strongest predictors of long-term health(1). Users can see how their lifestyle, for example exercise, nutrition, sleep, stress, shapes their biological age and immune fitness. Instead of guessing what improves health, users can base their decisions on their own cellular data, making longevity science personal, accessible, and actionable.
Recent research powerfully supports this vision. A study published in Nature Aging(2) demonstrated that a simple combination of regular exercise, Omega-3 supplementation, and Vitamin D can slow biological aging. These interventions boost immune health, reduce chronic inflammation, and reinforce cellular resilience. For athletes, they help maintain peak performance and protect long-term wellbeing. For fans, they offer scientifically-grounded ways to extend healthspan (the number of years lived in good health). By incorporating these findings into our strategy, Omniscope is promoting a lifestyle-based, data-driven approach to longevity that has the potential to benefit millions.
The most striking demonstration of Omniscope’s capabilities, however, comes from the world of clinical medicine. At Hospital Sant Joan de Déu, a very young patient with a rare and aggressive rhabdoid tumor had to be put through immunotherapy. Standard tests could not fully capture how her immune system was reacting, but Omniscope’s technology provided a level of insight that transformed her treatment(3). By monitoring the patient’s immune cells in extraordinary detail, clinicians could observe the emergence of tumor-specific T-cells, immune cells that had learned to recognize and attack the cancer. Omniscope’s profiling showed that these cells were actively eliminating tumor cells, offering a compelling biological explanation for her improving condition.
Today, more than three years after starting therapy, the patient is tumor-free and in complete remission - an outcome that is exceptionally rare for this type of cancer. But Omniscope did not stop there. Building on the insight that the patient’s immune cells could successfully recognize and kill the tumor, the team took the next step of engineering her own T-cells into a personalized cellular therapy. In doing so, they transformed the concept of using cells as biomarkers into using cells as living drugs. This marks a profound shift in medicine: immune cells are not only a universal biomarker of disease but powerful, adaptable treatments capable of learning and evolving with each patient.
By bringing together these revolutionary approaches - spanning elite sports medicine, immune diagnostics, longevity science, and personalized immunotherapy - FC Barcelona and Omniscope are creating a new Model of Age that is proactive, personalized, and deeply biological. Their partnership shows that the same science that keeps athletes performing at the highest level can also help fans monitor their aging, guide healthy lifestyle choices, and even contribute to life-saving medical breakthroughs.
This collaboration is far more than a sports science initiative. It is the beginning of a broader movement to empower individuals with biological knowledge, extend healthspan, and push the boundaries of what personalized medicine can achieve.
From the pitch to the clinic, from the training center to everyday life, FC Barcelona and Omniscope are redefining what it means to understand the human body and unlocking new possibilities for a healthier future.
1. Hallmarks of aging: An expanding universe. Cell (2023) Jan 19;186(2):243-278. doi: 10.1016/j.cell.2022.11.001.
2. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging (2025) Mar;5(3):376-385. doi: 10.1038/s43587-024-00793-y.
3. Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer. Annals of Oncology (2025) Sep;36(9):1096-1106. doi: 10.1016/j.annonc.2025.05.530.
